Drug Profile
Recombinant insulin aspart biosimilar - Biogenomics
Latest Information Update: 30 Nov 2022
Price :
$50
*
At a glance
- Originator Biogenomics
- Class Antihyperglycaemics; Insulins; Pancreatic hormones; Peptides
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 30 Nov 2022 Discontinued - Phase-I for Type 1 diabetes mellitus (In volunteers) in India (SC)
- 28 Jul 2022 Biogenomics completes enrolment in its phase-III trial in Type 2 diabetes mellitus in India (SC) (CTRI2019-04-018455)
- 28 Apr 2019 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In volunteers) in India (SC, Injection)